74 2021 ESG Report Transparency Responsible supply chain Product impact Climate change Introduction Healthy workforce and communities Appendices AMR is relevant: the role of awareness and education Global experts have identified several challenges that low- and middle-income countries face when addressing AMR. Global Health Policy Leaders Activation Kit Patients & Patient Advocacy Groups Activation Kit Healthcare and Policy Organizations Activation Kit There are too few trained microbiologists, few health facilities that routinely undertake bacterial culture and still fewer facilities that meet the requirements for accreditation. To respond to these challenges, BD and The London School of Hygiene & Tropical Medicine (LSHTM), together with a global advisory group of experts, have partnered to create two online courses. The first was launched in 2019 to educate participants about how diagnostics can be leveraged to reduce the inappropriate use of antibiotics, screen patients with resistant bacteria in healthcare settings and monitor AMR trends and the effectiveness of antibiotic stewardship strategies. This course, available in six languages, has since reached 13,000 participants in over 100 countries and continues to be available for users to access on the Futurelearn website . In January 2022, in response to the COVID-19 pandemic, BD again collaborated with LSHTM and launched a new online course focused on learnings from the COVID-19 response and the impact on global AMR programs, including the expanded adoption of diagnostic technologies during this time. The course, entitled “ Diagnostics for AMR: Building Back Better from the COVID-19 Pandemic ,” continues to be available on the platform. The launch of this course coincided with the Study UK campaign, the British Council and the GREAT Britain campaign that allows for free digital upgrades for learners who live in countries that are eligible for Official Development Assistance (ODA). Since its launch, more than 1,000 users have accessed the course. Raising awareness is crucial because AMR threatens everyone As the founding sponsor of the Antimicrobial Resistance Fighters Coalition (ARFC), BD supports education, training and partnerships across the globe to raise awareness of AMR and to change behaviors to help maintain the effectiveness of antibiotics for our future generations. The Superbugs and You podcast series , co-produced with Center for Infectious Disease Research & Policy (CIDRAP), has over 8,000 downloads. The Superbugs and You podcasts feature stories from advocates, physicians, artists, researchers, pharmacists and educators working across the U.S. South Africa, Russia, Germany, Australia, the U.K. and India. In planning the podcast series, the development team expected to hear stories of frightening illness and clinical frustration. What was unexpected were the ways in which these stories of fear morphed into tales of resilience, a better understanding of the suffering of others, the drive to fight stigma and a new outlook on life as fighting AMR and creating systems of empowerment became a vocation. With over 80,000 page views in 2021, the ARFC website has successfully engaged key stakeholders from around the world. It has provided facts about AMR and actions that we can take today to make change. The site was updated last year with Japanese translations to broaden impact. With over 7,000 followers on our organic social media channels and over 28 million impressions via paid social engagements, we have successfully engaged a global audience from 167 countries on the topic of drug-resistant infections. The newly launched ARFC Activation Kits contain communication tools for patient advocacy, healthcare and policy organizations. With over 5,000 downloads, the kits have reached a global audience ready to engage and make an impact against drug-resistant infections. BD remains committed to investing in innovations to combat AMR through the development of new diagnostics, devices and information systems that can help in clinical decision-making and reduce risks by: • Supporting inf ection control guidelines; • Expanding diagnostics t esting; and • A dvancing medication management. Halting and reversing this massive challenge will require the combined resources and efforts of both public and private sectors. AMR has no single solution, and the challenges cannot be solved without multiple players working collectively on a common AMR agenda. BD will continue to collaborate with global leaders around the world to address this urgent global health concern.